Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Anhui Kedgene Biotechnology

Main focus: Next generation T cell-based therapies

Company stage: Clinical

Diseases: Solid tumours

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Anhui, China

Website: https://www.ankebio.com/english/index.php

Anhui Kedgene Biotechnology develops next generation T cell-based therapies for solid tumour treatment. The company uses CRISPR to knock out PD-1 from its T cell products, in order to optimise efficacy and safety.

Tags

HashtagAnhui Kedgene Biotechnology Co.,Ltd

close
Search CRISPR Medicine